Organogenesis Holdings Inc. Class A (ORGO)
NASDAQ: ORGOHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ORGO stock chart
Technical analysisKey statistics
All statistics- Market cap
- $100.16M
- EPS (TTM)
- -$1.20
- Dividend yield
- None
- 52-week range
- 0.73 – 5.91
- Day range
- 0.7507 – 0.8163
- Volume / Avg
- 792.59K / 850.26K
- Beta
- —
- Shares outstanding
- 129.80M
52-week range
ORGO stock today
Shares of Organogenesis (ORGO) finished lower on Nov 20 at $0.7716, a drop of 2.23% or $0.0176 per share, versus the S&P 500's 3.70% decline. Shares are 86.9% below their 52-week high of $5.91, set on Dec 24, 2025 and 5.7% above the 52-week low of $0.73, near the bottom of the past year's range. ORGO is down 85.1% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 86.2%.
Organogenesis has posted a net loss over the last twelve months (EPS of -$1.20), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Organogenesis
Company profileOrganogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. Its advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barriers and extracellular matrix (ECM) scaffolds; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic foot ulcers (DFU); Dermagraft, a dermal substitute grown from human dermal fibroblasts to treat DFUs; NuShield, a dehydrated placental allograft and surgical barrier to provide a protective barrier and ECM scaffold to support native healing; PuraPly Antimicrobial (AM) and PuraPly SX, which are antimicrobial barriers for the management of open wounds in surgical settings; and CYGNUS Dual, VIA Matrix, and SimpliMax are placental tissue grafts used to treat chronic and acute wounds that can be stored at room temperature. The company also provides PuraPly MZ, a micronized version of PuraPly for the management of open wounds in surgical settings; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; and TransCyte, a bioengineered tissue scaffold that promotes burn healing.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Gary S. Gillheeney Sr.
- Headquarters
- Canton, MA
- Employees
- 854
- IPO year
- 2016
- Website
- organogenesis.com
Financial highlights
Full financialsIn fiscal 2025, Organogenesis generated $564.2 million in revenue, up 17.0% from fiscal 2024, its 2nd consecutive year of revenue growth. Net income was $37.0 million (+4201.0% year over year), for a net margin of 6.6% versus a median of 3.4% in the prior 5 years. Operating margin was 7.9%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $564.17M | $482.04M | $433.14M | $450.89M | $467.36M |
| Growth | +17.04% | +11.29% | -3.94% | -3.52% | +38.15% |
| Net income | $37.03M | $861.00K | $4.95M | $15.53M | $94.20M |
| EPS (diluted) | $0.15 | $-0.01 | $0.04 | $0.12 | $0.70 |
Analyst forecast
ForecastConsensus (2 analysts)
hold
- Strong buy 0
- Buy 0
- Hold 2
- Sell 0
- Strong sell 0
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 5, 2026
- EPS actual vs est.
- $-0.25 vs —
ORGO news
All ORGO news- Organogenesis: 3 Key Takeaways for Long-Term InvestorsNasdaqORGO, HEI.A
- Organogenesis (ORGO) Q3 2026 Earnings Call TranscriptNasdaq
- Organogenesis Holdings Inc. Reports Third Quarter 2026 Financial ResultsGlobeNewswire
- Organogenesis Announces Publication of Peer-Reviewed PREPARE Trial Results Demonstrating Clinical Benefit of PuraPly®AM for Hard-to-Heal Diabetic Foot UlcersGlobeNewswire
- Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2026 Financial Results on November 5, 2026GlobeNewswire
Organogenesis peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| NERVMinerva Neurosciences Inc | 2.00 | -5.66% | $99.67M | vs ORGO |
| CNTNCanton Strategic Holdings Inc. | 1.21 | -1.63% | $98.78M | vs ORGO |
| UNCYUnicycive Therapeutics Inc. | 3.35 | -5.10% | $97.77M | vs ORGO |
| FHTXFoghorn Therapeutics Inc. | 1.72 | -3.37% | $103.14M | vs ORGO |
| GNLXGenelux Corporation | 2.17 | -4.82% | $103.36M | vs ORGO |
| NBPNovaBridge Biosciences ADR | 0.83 | -5.66% | $96.28M | vs ORGO |
| PDSBPDS Biotechnology Corporation | 0.7774 | -3.70% | $95.39M | vs ORGO |
| NRXPNRX Pharmaceuticals Inc. | 2.15 | -15.69% | $95.31M | vs ORGO |
Indexes, lists and sector
Organogenesis stock FAQ
What is Organogenesis's stock price today?
ORGO last traded at $0.7716 as of Nov 20, 4:00 PM EST, down 2.23% on the day. Prices are delayed at least 15 minutes.
Who is Organogenesis's CEO?
Mr. Gary S. Gillheeney Sr. is the chief executive officer of Organogenesis Holdings Inc. Class A, which has about 854 employees.
What is the ORGO 52-week high?
The 52-week high for ORGO is $5.91 and the 52-week low is $0.73. The stock is currently 86.9% below its high.